Clinical trial
A Phase II Study of Capecitabine, Oxaliplatin and Bevacizumab for Metastatic or Unresectable Neuroendocrine Tumors
NCT00398320 is registered in ClinicalTrials.gov with Pamela L. Kunz as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of Capecitabine, Oxaliplatin and Bevacizumab for Metastatic or Unresectable Neuroendocrine Tumors
- Lead sponsor
- Pamela L. Kunz
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 30, 2006
- Completion date
- October 31, 2012
- Enrollment
- 40 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.